Instructions for Tivomax A oral solution 200 mg/ml bottle 200 ml
Composition
active ingredient: L-arginine L-aspartate;
1 ml of solution contains L-arginine L-aspartate 200 mg;
excipients: sorbitol (E 420), methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), sodium saccharin (E 954), caramel flavoring, purified water.
Dosage form
Oral solution.
Main physicochemical properties: slightly yellowish liquid with a caramel odor.
Pharmacotherapeutic group
Other cardiac drugs. Amino acids.
ATX code C01E.
Pharmacological properties
Pharmacodynamics
Tivomax® A has antihypoxic, cytoprotective, antioxidant, detoxification, membrane-stabilizing effects. It plays an important role in the processes of ammonia neutralization and stimulation of its excretion from the body, enhances the detoxification function of the liver. It has a hepatoprotective effect, positively affects the processes of energy supply in hepatocytes.
As a nitric oxide donor, Tivomax® A participates in the processes of energy supply of the body, reduces the activation and adhesion of leukocytes and platelets to the vascular endothelium, preventing the formation and development of atherosclerotic plaques, and is involved in the processes of fibrinogenolysis and spermatogenesis.
The drug has a moderate anabolic effect, stimulates the activity of the thymus gland, promotes insulin synthesis and regulates blood glucose levels during physical exertion, and helps correct acid-base balance.
Pharmacokinetics
Not studied.
Indication
Use in complex therapy of atherosclerosis of the heart and brain vessels, arterial hypertension, atherosclerosis of peripheral vessels; chronic heart failure; hypercholesterolemia; chronic obstructive pulmonary diseases, pulmonary hypertension; asthenic conditions.
Contraindication
Hypersensitivity to the active substance or to any of the excipients of the medicinal product. Severe renal impairment. Myocardial infarction (including history).
Interaction with other medicinal products and other types of interactions
When using arginine aspartate, it is necessary to take into account that the combined use of aminophylline with arginine may be accompanied by an increase in the content of insulin in the blood; spironolactone with arginine - an increase in the level of potassium in the blood. Arginine is incompatible with thiopental.
Application features
It should be used with caution in cases of electrolyte imbalance and kidney disease. When using the drug, it is necessary to adhere to a balanced sleep and rest regimen, and to avoid alcohol, nicotine, and psychostimulants. If symptoms of asthenia increase while taking the drug, treatment should be discontinued.
Use the drug with caution in patients with angina pectoris.
Patients with hereditary fructose intolerance should not take the drug.
The medicine contains sorbitol (E 420) - if the patient has been diagnosed with an intolerance to some sugars, you should consult a doctor before taking it.
The drug contains excipients such as methyl parahydroxybenzoate (E 218) and propyl parahydroxybenzoate (E 216), which may cause allergic reactions (possibly delayed).
This medicinal product contains less than 0.02 mmol (0.47 mg)/dose (5 ml) of sodium, i.e. essentially 'sodium-free'.
Use during pregnancy or breastfeeding
The drug penetrates the placenta, so it can be used during pregnancy only if the expected benefit to the mother outweighs the potential risk to the fetus.
There are no data on the use of the drug during breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Method of administration and doses
Administer orally, take with meals. Adults with atherosclerosis of the heart and brain vessels, atherosclerosis of peripheral vessels - 5 ml (1 measuring spoon - 1 g of the drug) 3-8 times a day. With hypercholesterolemia, arterial hypertension - 5 ml 3-6 times a day. With chronic obstructive pulmonary diseases, pulmonary hypertension - 5 ml 3-6 times a day. With asthenic conditions - 5 ml 4-8 times a day. The maximum daily dose is 8 g. The duration of the course of treatment is 8-15 days; if necessary, the course of treatment is repeated.
Children
Do not use in children (under 18 years of age).
Overdose
Symptoms: hypersensitivity reactions, hypoglycemic states.
Treatment. In the presence of these phenomena, it is necessary to stop taking the drug. Gastric lavage and sorbents are indicated. There is no antidote. Symptomatic therapy.
Side effects
Musculoskeletal system: joint pain.
On the part of the gastrointestinal tract: rarely - a feeling of mild discomfort in the stomach and intestines, nausea immediately after taking the drug, which disappear on their own.
The medicine contains excipients such as methyl parahydroxybenzoate, propyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed), and in some cases, bronchospasm.
Laboratory indicators: hyperkalemia.
Reporting of suspected adverse reactions.
Reporting suspected adverse reactions after the registration of a medicinal product is important. This allows monitoring of the benefit/risk ratio of the medicinal product. Medical and pharmaceutical professionals, as well as patients or their legal representatives, should report all cases of suspected adverse reactions and/or lack of efficacy of the medicinal product via the Automated Information System for Pharmacovigilance at the link: https://aisf.dec.gov.ua.
Expiration date
1.5 years.
The shelf life after opening the bottle is 14 days.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ° C. Do not freeze.
Keep out of reach of children.
Packaging
100 ml or 200 ml in a bottle; 1 bottle with a measuring spoon or measuring cup in a pack.
Vacation category
Without a prescription.
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Address
Ukraine, 02093, Kyiv, Boryspilska St., 13.
